Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 3 2Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × lutetium Lu 177 dotatate × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Sinotau Pharmaceutical Group

Phase 3 Active not recruiting
196 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡